Please login to the form below

Not currently logged in

US CROs to report payments to physicians

New rules to US ‘Sunshine Act’ also apply to CMOs

US contract research organisations (CROs) and contract manufacturing organisation (CMOs) must now declare any payments made to physicians, under new federal regulations impacting the pharmaceutical industry.

The Transparency Report and Reporting of Physician Ownership or Investment Interests, commonly known as the 'Sunshine Act', will require manufacturers of drugs, devices, biological or medical supplies to report payments made to physicians on an annual basis.

The new rules fall under the Patient Protection and Affordable Care Act (ACA) section of the act and apply to companies functioning within US health programmes Medicare, Medicaid or CHIP.

The ruling, released last week, also applies to both CMOs and CROs and will cover "payments and transfers of value", including consulting fees, honoraria, gifts, travel and entertainment.

From August 2013 companies will need to begin collecting data on payments made to physicians, which will then be submitted to the Department of Health and Human Services' (HHS) Centers for Medicare and Medicaid Services (CMS), by the end of March 2014.

"The intent of this law is to bring potential conflicts of interest to light with the goal of driving down healthcare costs," explained Scott Liebman, principal at Porzio, Bromberg & Newman, speaking to Forbes.

14th February 2013

From: Research, Regulatory



Related Hub content

Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...